Grunenthal Archives -

Whether you’re a large pharma company or a small, emerging one, communication is key. Success or failure hinges

Is your digital communication strategy up to par?

https://pharmaphorum.com/webinars/is-your-digital-communication-strategy-up-to-par/

Sales and Marketing/ Views & Analysis/ Views and analysis

4 principles for the future of pharma marketing

mike.hammerton@pharmaphorum.com AI, artificial intelligence, Grunenthal, marketing, pharma marketing 0 Comment

COVID-19 has disrupted markets and accelerated digital adoption but what does this mean for the future of marketing?

4 principles for the future of pharma marketing

https://pharmaphorum.com/views-analysis-sales-marketing/4-principles-future-pharma-marketing/

Market Access/ News/ News

AstraZeneca sells rights to cholesterol drug Crestor to Grunenthal

Richard Staines AstraZeneca, cholesterol, Crestor, generics, Grunenthal, M&A 0 Comment

AstraZeneca is to sell European rights to its cholesterol drug Crestor (rosuvastatin) to Germany’s Grunenthal. Crestor is a

AstraZeneca sells rights to cholesterol drug Crestor to Grunenthal

https://pharmaphorum.com/news/astrazeneca-sells-rights-to-cholesterol-drug-crestor-to-grunenthal/

Sales and Marketing/ Views & Analysis/ Views and analysis

How COVID-19 is changing the sales model

George Underwood coronavirus, COVID-19, Grunenthal, Pharma Sales, Sales reps, virtual sales 0 Comment

The COVID-19 pandemic means that reps can no longer speak face-to-face with physicians and many HCPs simply don’t

How COVID-19 is changing the sales model

https://pharmaphorum.com/views-analysis-sales-marketing/covid-19-changing-sales-model/

News

Mundipharma, Grünenthal accused of kickbacks in Italy

Phil Taylor Grunenthal, Mundipharma, opioid 0 Comment

Two manufacturers of opioid analgesics – Mundipharma and Grünenthal – have been accused of paying an Italian doctor

Mundipharma, Grünenthal accused of kickbacks in Italy

https://pharmaphorum.com/news/mundipharma-grunenthal-italy-opioid/

Digital/ News/ News

Grünenthal buys certain rights to AZ’s Nexium and Vimovo for $922m

Joy Persaud AstraZeneca, Grunenthal, Nexium, Vimeo 0 Comment

AstraZeneca has agreed to sell some of the rights to its drugs Nexium and Vimovo to Grünenthal for

Grünenthal buys certain rights to AZ’s Nexium and Vimovo for $922m

https://pharmaphorum.com/news/grunenthal-buys-certain-rights-to-azs-nexium-and-vimovo-for-922m/

Market Access/ News/ News

AZ considers options as US gout drug deal backfires

Richard Staines AstraZeneca, gout, Grunenthal, Ironwood, market access 0 Comment

Ironwood tears up licensing agreement after sales disappoint

AZ considers options as US gout drug deal backfires

https://pharmaphorum.com/news/az-considers-options-drug-deal-backfires/

News/ UK & Europe

AZ sells migraine drug rights to Grunenthal for $300m

Richard Staines AstraZeneca, Grunenthal, migraine, neurology 0 Comment

AZ says migraine outside its strategic focus.

AZ sells migraine drug rights to Grunenthal for $300m

https://pharmaphorum.com/news/az-sells-zomig-300m/

AstraZeneca/ News

Five UK pharma companies “named and shamed” by watchdog

Richard Staines AstraZeneca, Boehringer Ingelheim, code of practice, Eli Lilly, Grunenthal, Janssen, PMCPA 0 Comment

Companies’ actions discredited the industry, says PMCPA.

Five UK pharma companies “named and shamed” by watchdog

https://pharmaphorum.com/news/five-pharmas-named-shamed-pmcpa/

Trending

Grunenthal

Login